Current status of endomyocardial biopsy

Aaron M. From, Joseph Maleszewski, Charanjit S. Rihal

Research output: Contribution to journalReview article

115 Citations (Scopus)

Abstract

Endomyocardial biopsy (EMB) is widely used for surveillance of cardiac allograft rejection and for the diagnosis of unexplained ventricular dysfunction. Typically, EMB is performed through the jugular or femoral veins and is associated with a serious acute complication rate of less than 1% using current flexible bioptomes. Although it is accepted that EMB should be used to monitor for rejection after transplant, use of EMB for the diagnosis of various myocardial diseases is controversial. Diagnosis of myocardial disease in the nontransplant recipient is often successful via noninvasive investigations including laboratory evaluation; echocardiography, nuclear studies, and magnetic resonance imaging can yield specific diagnoses in the absence of invasive EMB. Therefore, use of the technique is patient specific and depends on the potential prognostic and treatment information gained by establishing a pathologic diagnosis beyond noninvasive testing.

Original languageEnglish (US)
Pages (from-to)1095-1102
Number of pages8
JournalMayo Clinic Proceedings
Volume86
Issue number11
DOIs
StatePublished - 2011

Fingerprint

Biopsy
Cardiomyopathies
Ventricular Dysfunction
Femoral Vein
Jugular Veins
Graft Rejection
Allografts
Echocardiography
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current status of endomyocardial biopsy. / From, Aaron M.; Maleszewski, Joseph; Rihal, Charanjit S.

In: Mayo Clinic Proceedings, Vol. 86, No. 11, 2011, p. 1095-1102.

Research output: Contribution to journalReview article

From, Aaron M. ; Maleszewski, Joseph ; Rihal, Charanjit S. / Current status of endomyocardial biopsy. In: Mayo Clinic Proceedings. 2011 ; Vol. 86, No. 11. pp. 1095-1102.
@article{2755ed7c4df340459d463db138d90abc,
title = "Current status of endomyocardial biopsy",
abstract = "Endomyocardial biopsy (EMB) is widely used for surveillance of cardiac allograft rejection and for the diagnosis of unexplained ventricular dysfunction. Typically, EMB is performed through the jugular or femoral veins and is associated with a serious acute complication rate of less than 1{\%} using current flexible bioptomes. Although it is accepted that EMB should be used to monitor for rejection after transplant, use of EMB for the diagnosis of various myocardial diseases is controversial. Diagnosis of myocardial disease in the nontransplant recipient is often successful via noninvasive investigations including laboratory evaluation; echocardiography, nuclear studies, and magnetic resonance imaging can yield specific diagnoses in the absence of invasive EMB. Therefore, use of the technique is patient specific and depends on the potential prognostic and treatment information gained by establishing a pathologic diagnosis beyond noninvasive testing.",
author = "From, {Aaron M.} and Joseph Maleszewski and Rihal, {Charanjit S.}",
year = "2011",
doi = "10.4065/mcp.2011.0296",
language = "English (US)",
volume = "86",
pages = "1095--1102",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Current status of endomyocardial biopsy

AU - From, Aaron M.

AU - Maleszewski, Joseph

AU - Rihal, Charanjit S.

PY - 2011

Y1 - 2011

N2 - Endomyocardial biopsy (EMB) is widely used for surveillance of cardiac allograft rejection and for the diagnosis of unexplained ventricular dysfunction. Typically, EMB is performed through the jugular or femoral veins and is associated with a serious acute complication rate of less than 1% using current flexible bioptomes. Although it is accepted that EMB should be used to monitor for rejection after transplant, use of EMB for the diagnosis of various myocardial diseases is controversial. Diagnosis of myocardial disease in the nontransplant recipient is often successful via noninvasive investigations including laboratory evaluation; echocardiography, nuclear studies, and magnetic resonance imaging can yield specific diagnoses in the absence of invasive EMB. Therefore, use of the technique is patient specific and depends on the potential prognostic and treatment information gained by establishing a pathologic diagnosis beyond noninvasive testing.

AB - Endomyocardial biopsy (EMB) is widely used for surveillance of cardiac allograft rejection and for the diagnosis of unexplained ventricular dysfunction. Typically, EMB is performed through the jugular or femoral veins and is associated with a serious acute complication rate of less than 1% using current flexible bioptomes. Although it is accepted that EMB should be used to monitor for rejection after transplant, use of EMB for the diagnosis of various myocardial diseases is controversial. Diagnosis of myocardial disease in the nontransplant recipient is often successful via noninvasive investigations including laboratory evaluation; echocardiography, nuclear studies, and magnetic resonance imaging can yield specific diagnoses in the absence of invasive EMB. Therefore, use of the technique is patient specific and depends on the potential prognostic and treatment information gained by establishing a pathologic diagnosis beyond noninvasive testing.

UR - http://www.scopus.com/inward/record.url?scp=80055098518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055098518&partnerID=8YFLogxK

U2 - 10.4065/mcp.2011.0296

DO - 10.4065/mcp.2011.0296

M3 - Review article

C2 - 22033254

AN - SCOPUS:80055098518

VL - 86

SP - 1095

EP - 1102

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -